HHS Opens 503A Compounding for Six Peptides: What the October 30 Policy Does and Doesn’t Do

HHS Opens 503A Compounding for Six Peptides: What the October 30 Policy Does and Doesn't Do

By Medical Team of Generic Peptides

On October 28, 2026, the U.S. Department of Health and Human Services (HHS) filed a notice with the Federal Register announcing an "Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances." The notice is scheduled for official publication on October 30, 2026. It covers six peptides: BPC-157, Epitalon, KPV, MOTS-c, Semax and TB-500 [1, 2].

Social media posts have described this as the six peptides becoming "legal to prescribe." That is only partly accurate. Below we explain what the policy actually says, what conditions it sets, and what it does not change.

What HHS Announced

The policy is an HHS document (Docket No. HHS-OASH-2026-0496, RIN 0910-ZD94), signed by HHS Secretary Robert F. Kennedy, Jr. It is the same regulatory action we reported on when it was sent to the White House Office of Management and Budget for review on October 14 (our earlier report) [1, 3].

In short, HHS states that it does not intend to take enforcement action against a state-licensed pharmacy, a federal facility, or a licensed physician that compounds a drug product using one of the six listed peptides, as long as specific conditions are met. The policy applies until each peptide is addressed in a final rule on the 503A bulks list, the list of bulk drug substances that pharmacies may use for compounding under section 503A of the Federal Food, Drug, and Cosmetic Act [2].

The notice describes the document as a draft and invites written comments on regulations.gov for two weeks after publication [1].

The Six Peptides Covered

Appendix A of the policy lists:

1. BPC-157
2. Epitalon
3. KPV
4. MOTS-c
5. Semax
6. TB-500

These are the same six peptides that FDA's Pharmacy Compounding Advisory Committee (PCAC) voted to recommend for the 503A bulks list at its July 23–24, 2026 meeting (meeting overview). The committee voted against a seventh, emideltide (DSIP) (our report), which is not included [2, 4].

The Conditions

Enforcement discretion applies only when all of the policy's conditions are met. In summary [2]:

• Listed substance only. The peptide must appear in Appendix A.
• Defined identity. The bulk peptide must match the identity described in Appendix B, including amino acid sequence, chemical structure, molecular weight and molecular formula. Appendix B also limits each peptide to specific routes of administration.
• Certificate of analysis. The bulk substance must come from an FDA-registered facility and have a valid certificate of analysis (COA) with test results for identity, purity, potency, and contaminants such as endotoxins, heavy metals and microbes.
• Registered original manufacturer. The original manufacturer (not a repacker or distributor) must be registered with FDA and comply with current good manufacturing practice (CGMP). Repackers or resellers must validate the manufacturer and its COA.
• Reporting. Compounders must report products compounded, serious adverse events and product quality problems to FDA's MedWatch program and to the relevant states.
• Labeling. Products must carry the statement "This is a compounded drug product. Not for resale."
• Single ingredient. Each compounded product may contain only one listed peptide. Combinations are excluded, which HHS says makes adverse events easier to attribute.
• Oral products. For oral forms, the compounder must document adequate oral bioavailability in humans.
• Devices. The only delivery device that may be packaged with the product is an FDA 510(k)-cleared syringe.
• Other requirements. All other requirements still apply, including section 503A's requirement for a valid patient-specific prescription.

The COA and manufacturer requirements are notable. They match the documentation that quality-focused suppliers already provide, and they are described in more detail in our guide to reading a peptide COA.

What the Policy Does Not Do

• It is not FDA approval. HHS states that compounded drugs are not FDA-approved, and none of the six peptides is an approved drug [2].
• It does not add the peptides to the 503A bulks list. That still requires FDA rulemaking. FDA "may propose" adding some or all of them in future rulemaking [1].
• It is not permanent or binding. The document "does not establish any rights for any person and is not binding on HHS or the public," and HHS may revisit it if a safety signal or product quality issue arises [1].
• It is limited to 503A compounding. It addresses state-licensed pharmacies, federal facilities and licensed physicians compounding for individual patients. State pharmacy and medical boards keep their own rules [2, 5].
• It does not cover research-use-only products. The policy concerns bulk substances used in pharmacy compounding, not compounds sold for laboratory research.

Why HHS Says It Acted

HHS gives two main reasons. First, it cites the PCAC meetings and peptide utilization data as evidence of significant interest in these peptides given the lack of approved products. Second, it states that the policy is meant to discourage the widespread use of research-use-only peptides from foreign manufacturers, which it says pose a safety risk to US patients, by providing "a more controlled alternative" [2].

FDA's own staff had raised concerns at the July meeting about the limited human safety and efficacy data for several of these peptides (our report). The policy does not resolve those scientific questions; it sets conditions for compounding while they remain open.

So, Is BPC-157 Legal Now?

The short answer for BPC-157 and the other five peptides is more nuanced than "yes":

• A licensed prescriber can write a patient-specific prescription, and a state-licensed 503A pharmacy can compound the peptide without facing HHS enforcement, if every condition of the policy is met and state law allows it.
• BPC-157 is still not FDA-approved, and it is still not on the final 503A bulks list.
• Products sold for research use only remain research products, and the policy does not change how they may be marketed or used.

For background on the science behind each peptide, see our research guides on BPC-157, TB-500, Semax and Epitalon.

What Happens Next

• Comment period: written comments are open on regulations.gov (Docket No. HHS-OASH-2026-0496) for two weeks after publication [1].
• Rulemaking: FDA may propose adding some or all six peptides to the 503A bulks list through notice-and-comment rulemaking [1].
• More peptides: a second PCAC meeting on other peptides, including GHK-Cu, LL-37, dihexa, melanotan II and PEG-MGF, has been reported as expected by early 2027 [5].
• State response: states may follow, adjust or restrict the federal approach for their own licensees [5].

We will update this page when the policy is published and if HHS revises it.

FAQ

Which peptides does the HHS policy cover?

BPC-157, Epitalon, KPV, MOTS-c, Semax and TB-500, as listed in Appendix A of the policy.

Does this mean BPC-157 is FDA-approved?

No. The policy is enforcement discretion for 503A compounding. BPC-157 and the other five peptides are not FDA-approved drugs.

When does the policy take effect?

The notice was filed on October 28, 2026 and is scheduled for publication in the Federal Register on October 30, 2026. Comments are accepted for two weeks after publication.

Does the policy apply to research-use-only peptides?

No. It addresses bulk substances used by licensed pharmacies and physicians for patient-specific compounding. HHS describes the policy as an alternative to the use of research-use-only peptides in patients.

References